Jordana B. Cohen, Raymond R. Townsend, et al.
J Am Coll Cardiol CardioOnc. 2019 Dec, 1 (2) 252–255
CARDIONCOLOGY.ORG ABSTRACT:
Many agents including mitomycin C, ifosfamide, vincristine, cyclophosphamide, and clofarabine have been associated with a high risk of cancer therapy–related cardiac dysfunction (CTRCD).
This study examined the data on which the therapy-CTRCD associated was based. Their results suggest problems with the manner in which trials were conducted and the interpretation of the findings.
The authors suggest that cardiotoxicity of the cancer therapies must be re-evaluated.
Go to cardioncology.org list of contents of this JACC CardioOncology issue
© All Rights Reserved